NEJM上刊登公布了中國科興(CoronaVac)疫苗在智利前瞻施打的結果
打完兩劑科興疫苗之後，接種者減少65.9%感染，87.5%住院，90.3%ICU重症，86.3%死亡！
過去台灣新聞常常報導中國科興疫苗的負面新聞，而中國科興疫苗在智利也順利的完成總共一千萬人的前瞻試驗結果分析！而這個臨床試驗主要九成都在智利進行！
研究發現打完兩劑的中國科興(CoronaVac)疫苗可以提供足夠的保護效力！打完兩劑科興疫苗之後，受試者減少65.9%感染，87.5%住院，90.3%ICU重症，86.3%死亡！
而60歲以上的長者施打科興疫苗也能得到一樣的保護力！
本研究沒有提供完整的病毒株差異的分析，不過採樣了當時智利的病毒株，看起來智利是混合各式各樣的病毒株！
但是沒有Delta變種病毒株，所以這篇研究無法得知Delta病毒株的保護力。
而研究也發現，如果只打一劑的中國科興(CoronaVac)疫苗，則不能得到保護力，所以想打科興疫苗的民眾，記得務必要打兩劑才可以！
https://www.nejm.org/doi/full/10.1056/NEJMoa2107715
同場加映，科興疫苗在土耳其的一萬人第三期臨床試驗顯示，打完科興疫苗兩劑後可以提供83.5%的保護力！！
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)01429-X/fulltext
Among 11 303 volunteers screened between Sept 14, 2020, and Jan 5, 2021, 10 218 were randomly allocated. After exclusion of four participants from the vaccine group because of protocol deviations, the intention-to-treat group consisted of 10 214 participants (6646 [65·1%] in the vaccine group and 3568 [34·9%] in the placebo group) and the per protocol group consisted of 10 029 participants (6559 [65·4%] and 3470 [34·6%]) who received two doses of vaccine or placebo. During a median follow-up period of 43 days (IQR 36–48), nine cases of PCR-confirmed symptomatic COVID-19 were reported in the vaccine group (31·7 cases [14·6–59·3] per 1000 person-years) and 32 cases were reported in the placebo group (192·3 cases [135·7–261·1] per 1000 person-years) 14 days or more after the second dose, yielding a vaccine efficacy of 83·5% (95% CI 65·4–92·1; p<0·0001). The frequencies of any adverse events were 1259 (18·9%) in the vaccine group and 603 (16·9%) in the placebo group (p=0·0108) with no fatalities or grade 4 adverse events. The most common systemic adverse event was fatigue (546 [8·2%] participants in the vaccine group and 248 [7·0%] the placebo group, p=0·0228). Injection-site pain was the most frequent local adverse event (157 [2·4%] in the vaccine group and 40 [1·1%] in the placebo group, p<0·0001).
沒有留言:
張貼留言